Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company headquartered in Houston, Texas, with news flow centered on its regulatory T cell (Treg)–focused pipeline for neurodegenerative and inflammation-driven diseases. Company updates frequently highlight progress with COYA 302, an investigational proprietary biologic combination of low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, and COYA 303, an investigational combination of LD IL-2 and a GLP-1 receptor agonist.
Investors following COYA news can expect regular coverage of clinical trial milestones, including the Phase 2 ALSTARS Trial of COYA 302 in amyotrophic lateral sclerosis (ALS). Coya has announced key events such as FDA acceptance of its IND for COYA 302 in ALS, Health Canada’s acceptance of a Clinical Trial Application, initiation and dosing of patients in the ALSTARS Trial, and milestone payments received under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd.
News items also describe regulatory developments for frontotemporal dementia (FTD), including FDA acceptance of an IND for COYA 302 in FTD and results from an investigator-initiated open-label study of low-dose IL-2 and CTLA4-Ig in FTD patients. Additional releases cover preclinical data for COYA 303 in an in vivo model of systemic and neurologic inflammation, corporate financing activities such as an upsized public offering of common stock, and quarterly financial results and corporate updates.
This COYA news page aggregates these disclosures so readers can review clinical, regulatory, scientific, and financing announcements in one place. For those tracking Treg-based approaches to ALS, FTD, Alzheimer’s disease, and related conditions, the news stream provides direct access to Coya’s reported data, trial status updates, and key corporate events over time.
Coya Therapeutics (NASDAQ: COYA) reported results from a 9-patient, investigator-initiated open-label study of low-dose IL-2 plus CTLA4-Ig in frontotemporal dementia over 22 weeks of dosing. The study observed statistically significant increases in regulatory T-cell (Treg) numbers and suppressive function beginning at two weeks and sustained through week 22. Cognitive measures remained stable: MoCA (baseline 13.5, week 22 14) and CDR-FTLD (baseline 4.8, week 22 5.5) showed no meaningful decline. Safety was tolerable with no serious adverse events and injection-site erythema in 33.3% of participants. Company commented on advancing COYA 302 to a controlled Phase 2 trial.
Coya Therapeutics (NASDAQ: COYA) announced that the U.S. FDA has accepted its IND for COYA 302 to treat frontotemporal dementia (FTD) on January 5, 2026. FTD affects about 60,000 Americans, has an average onset age of 58 and average survival of 7.5 years. The company positions COYA 302 to enhance regulatory T cell (Treg) anti-inflammatory function as a disease‑modifying approach for sporadic FTD. Coya also expects to announce topline results soon from an investigator‑initiated open‑label study evaluating low‑dose IL‑2 and CTLA4‑Ig in mild‑to‑moderate FTD.
Coya Therapeutics (NASDAQ: COYA) announced that Health Canada accepted the Clinical Trial Application for COYA 302 on December 23, 2025, allowing activation of Canadian clinical sites for the ALSTARS phase 2 placebo‑controlled trial in amyotrophic lateral sclerosis (ALS).
The CTA acceptance permits patient enrollment at Canadian ALS centers, expanding recruitment alongside ongoing U.S. sites and enabling broader site activation and patient access for the study.
Coya Therapeutics (NASDAQ: COYA) announced on December 9, 2025 that dosing of ALS patients has commenced in the Phase 2 ALSTARS Trial of COYA 302.
ALSTARS is a multi-center, randomized, double-blind, placebo-controlled study enrolling patients in the United States and Canada to assess safety and efficacy of COYA 302, a combination of low-dose IL-2 and CTLA-4 Ig designed to boost regulatory T cells and suppress pro-inflammatory myeloid activity in ALS.
The company will receive a $4.2 million milestone payment from strategic partner Dr. Reddy’s Laboratories tied to this dosing milestone.
Coya Therapeutics (NASDAQ: COYA) announced that company management will participate in two investor and scientific conferences on December 2, 2025. CEO Dr. Arun Swaminathan will appear in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami from 8:45–9:05 am ET with a live webcast available.
CMO Dr. Fred Grossman will join a roundtable at the 18th CTAD Conference in San Diego from 3:10–3:50 pm ET titled “Charting the Path Forward for Combination Therapy in Alzheimer’s Disease.” Webcasts and archived replays will be available on the company’s Investor Relations Events and Presentations page, with replays accessible for 90 days.
ReAlta Life Sciences (AVIR) appointed Howard Berman, Ph.D. as Executive Chairman effective immediately on November 25, 2025. The company said Dr. Berman brings more than 20 years of biopharma leadership across company formation, clinical development, strategic partnerships, and public-market execution.
ReAlta highlighted pegtarazimod's clinical data and safety profile across three life-threatening diseases and said the peptide platform targets complement and neutrophil-driven inflammation. Dr. Berman currently chairs Coya Therapeutics and serves on the board of Atea Pharmaceuticals.
Coya Therapeutics (NASDAQ: COYA) launched the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled 24-week study of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) (ClinicalTrials.gov: NCT 07161999).
The study will enroll 120 participants across approximately 25 centers in the United States and Canada. Participants completing the 24-week placebo-controlled phase may join a 24-week blinded extension during which all participants will receive COYA 302 at one of two prespecified doses. Study details and eligibility are available on the trial registry. The trial will be presented on September 29, 2025 during a NEALS educational webinar.
Coya Therapeutics (NASDAQ: COYA) reported Q3 2025 results and a corporate update: the FDA accepted the IND for COYA 302 in ALS and Coya launched the Phase 2 ALSTARS trial (NEALS-affiliated). The company received a $4.2M milestone from Dr. Reddy’s and closed an upsized public offering of $23.0M, extending cash runway into 2H 2027. Cash and equivalents were $28.1M at September 30, 2025. Q3 collaboration revenue was $3.6M (including $3.3M license revenue on IND acceptance). R&D expenses were $2.9M, G&A $2.6M, and net loss was $2.1M for the quarter.
Coya Therapeutics (NASDAQ: COYA) reported results from a completed in vivo mouse study of its investigational combination COYA 303 (low-dose IL-2 + GLP-1 receptor agonist) in a lipopolysaccharide (LPS) model of systemic and neurologic inflammation on November 4, 2025. The company said COYA 303 reduced peripheral pro-inflammatory cell expansion, enhanced regulatory T cell (Treg) activation and function, attenuated CNS inflammation, and shifted monocytes/macrophages toward an anti-inflammatory phenotype versus controls.
Coya noted the study confirmed interim findings, used daily LPS injections for five days with COYA 303 given for four days, and plans to publish a full dataset. Management linked these preclinical effects to potential development in neurodegenerative and autoimmune diseases and referenced upcoming semaglutide Alzheimer’s trial readouts as strategic context.
Coya Therapeutics (NASDAQ: COYA) closed an underwritten public offering raising approximately $23.0 million through the sale of 4,181,818 shares of common stock at a public offering price of $5.50 per share, including 545,454 additional shares sold upon full exercise of the underwriter’s option.
The company said gross proceeds were approximately $23.0 million before underwriting discounts, commissions, and offering expenses. Coya intends to use net proceeds for working capital, general corporate purposes, and to fund its clinical development plan. Lucid Capital Markets served as book-running manager.
FAQ
What is the current stock price of Coya Therapeutics (COYA)?
What is the market cap of Coya Therapeutics (COYA)?
